Maven Securities’s Day One Biopharmaceuticals DAWN Stock Holding History

Maven Securities’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Buy	+103,900	New	+$1.46M	0.04%	255
2023 Q2	–	Sell	-100,000	Closed	-$1.34M	–	902
2023 Q1	$1.34M	Buy	+100,000	New	+$1.95M	0.03%	386
2022 Q3	–	Sell	-80,000	Closed	-$1.43M	–	1116
2022 Q2	$1.43M	Buy	+80,000	New	+$826K	0.04%	283
2021 Q3	–	Sell	-9,000	Closed	-$210K	–	1091
2021 Q2	$210K	Buy	+9,000	New	+$188K	0.01%	930

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Maven Securities's DAWN Position: Q1 2026 in Review

Maven Securities opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 103,900 shares worth $2.23M. The stake represents 0.04% of the portfolio and ranks #255 among its holdings. This is a return to the name: Maven Securities previously reported a position in DAWN as recently as Q1 2023.

Maven Securities first reported a position in DAWN in Q2 2021 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Maven Securities held 103,900 shares of Day One Biopharmaceuticals worth $2.23M as of Q1 2026.
Day One Biopharmaceuticals was a new Maven Securities position in Q1 2026.
Day One Biopharmaceuticals made up 0.04% of Maven Securities's portfolio in Q1 2026, its #255 holding.
Maven Securities first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 4 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.